Kimberly-Clark is preparing to give something up to get something big. The maker of Kleenex and Huggies wants to absorb Kenvue, the company behind Tylenol, Listerine, Aveeno, and Neutrogena, in a $40 billion deal. But first, European regulators need convincing, and Kimberly-Clark is readying asset sales to make that case.

According to people familiar with the matter, the European Commission is expected to formally tell Kimberly-Clark this week exactly what competition concerns it has with the merger. That kicks off a critical window: Kimberly-Clark can either sell off pieces of the combined company now, during the regulator's preliminary review period (which closes September 29), or wait and face a full four-month investigation. Offering concessions early is the faster path to a green light.

What they might have to sell, and why it matters

The deal has already moved through two other markets with conditions attached. Australia approved it last week, but required Kimberly-Clark to divest Kenvue's Carefree and Stayfree period care brands there. South Africa signed off last month under similar terms. The European Commission tends to run its own analysis, so what gets sold in Brussels may look different from what got sold in Sydney, but the pattern is clear: regulators see market concentration risk in specific product categories and want a competitor standing in those spaces before they say yes.

For ordinary consumers, that matters more than it might sound. When two large consumer goods companies merge, the combined entity can quietly reduce the competitive pressure that keeps prices in check and product variety alive. If Kimberly-Clark acquires Kenvue's full lineup without conditions, it controls a sweeping share of the personal care aisle, from diapers to mouthwash to skincare. Antitrust divestitures are designed to keep at least one rival brand viable in the categories where that concentration is sharpest.

The deal's larger context

This merger was announced in November last year, at a moment when consumer goods companies were facing real pressure from cautious shoppers hunting for value. Brands have been responding by shrinking pack sizes and cutting underperforming lines. Kimberly-Clark's logic in buying Kenvue is partly defensive: more brands, more shelf space, more pricing power in a market where volume growth is hard to find.

That same logic is exactly what competition regulators are trained to scrutinize. A company that controls more of the shelf has less reason to compete on price, and more ability to squeeze out private-label alternatives that budget-conscious shoppers rely on.

Kimberly-Clark's bet is that it can satisfy European regulators with targeted divestitures, the same way it already satisfied Australian and South African authorities, without giving up so much that the $40 billion price tag stops making sense. If the Commission's concerns are narrow enough, that is probably achievable. If Brussels flags a broader set of overlapping categories, the negotiation gets harder and the timeline stretches.

The September 29 deadline is the one to watch. If Kimberly-Clark submits acceptable concessions before then, the deal could clear without triggering a deeper probe. If it doesn't, both companies spend another four months in regulatory limbo, and the consumer goods market that both depend on keeps shifting underneath them.